Point-of-Care Molecular Diagnostics Market Projected to Double by 2034
Event summary
- The global point-of-care molecular diagnostics market was valued at USD 8.46 billion in 2024 and is expected to reach USD 17.94 billion by 2034, growing at a CAGR of 8.70%.
- Infectious disease testing dominates the application segment with approximately 60% market share due to the urgent need for rapid pathogen identification.
- North America leads the market with a 42% share in 2024, driven by advanced healthcare infrastructure and favorable clinical reimbursement programs.
The big picture
The point-of-care molecular diagnostics market is expanding rapidly due to the growing need for decentralized, rapid genetic testing in infectious disease management. This shift is driven by technological advancements and structural changes in healthcare delivery, particularly the rise of outpatient centers. The market's growth is further fueled by the urgent clinical demand for reducing patient hospital stay durations and optimizing staff workflows.
What we're watching
- Technological Advancements
- The integration of next-generation isothermal amplification systems and CRISPR technology will drive market value expansion.
- Regulatory Challenges
- Navigating strict regulatory approval frameworks remains a significant barrier to faster market penetration.
- Competitive Dynamics
- Intense price competition from low-cost immunoassay tests poses a persistent challenge for premium molecular device suppliers.
Related topics